5m3d: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Structural tuning of CD81LEL (space group P31)== | ==Structural tuning of CD81LEL (space group P31)== | ||
<StructureSection load='5m3d' size='340' side='right' caption='[[5m3d]], [[Resolution|resolution]] 2.38Å' scene=''> | <StructureSection load='5m3d' size='340' side='right'caption='[[5m3d]], [[Resolution|resolution]] 2.38Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5m3d]] is a 4 chain structure with sequence from [ | <table><tr><td colspan='2'>[[5m3d]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5M3D OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5M3D FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.38Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | ||
< | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5m3d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5m3d OCA], [https://pdbe.org/5m3d PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5m3d RCSB], [https://www.ebi.ac.uk/pdbsum/5m3d PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5m3d ProSAT]</span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Disease == | == Disease == | ||
[ | [https://www.uniprot.org/uniprot/CD81_HUMAN CD81_HUMAN] Defects in CD81 are the cause of immunodeficiency common variable type 6 (CVID6) [MIM:[https://omim.org/entry/613496 613496]; also called antibody deficiency due to CD81 defect. CVID6 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.<ref>PMID:20237408</ref> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/CD81_HUMAN CD81_HUMAN] May play an important role in the regulation of lymphoma cell growth. Interacts with a 16-kDa Leu-13 protein to form a complex possibly involved in signal transduction. May act as the viral receptor for HCV. | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 22: | Line 21: | ||
</div> | </div> | ||
<div class="pdbe-citations 5m3d" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5m3d" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[CD81|CD81]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Abrescia | [[Category: Large Structures]] | ||
[[Category: Cunha | [[Category: Abrescia NG]] | ||
[[Category: Hospital | [[Category: Cunha ES]] | ||
[[Category: Orozco | [[Category: Hospital A]] | ||
[[Category: Rojas | [[Category: Orozco M]] | ||
[[Category: Roversi | [[Category: Rojas AL]] | ||
[[Category: Sfriso | [[Category: Roversi P]] | ||
[[Category: Sfriso P]] | |||
Latest revision as of 21:23, 1 November 2023
Structural tuning of CD81LEL (space group P31)Structural tuning of CD81LEL (space group P31)
Structural highlights
DiseaseCD81_HUMAN Defects in CD81 are the cause of immunodeficiency common variable type 6 (CVID6) [MIM:613496; also called antibody deficiency due to CD81 defect. CVID6 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.[1] FunctionCD81_HUMAN May play an important role in the regulation of lymphoma cell growth. Interacts with a 16-kDa Leu-13 protein to form a complex possibly involved in signal transduction. May act as the viral receptor for HCV. Publication Abstract from PubMedHepatitis C virus (HCV) enters into human hepatocytes via tetraspanin hCD81. HCV glycoprotein E2 recognizes the "head" subdomain of the large extracellular loop (LEL) of CD81 (hCD81LEL), but the precise mechanism of virus cell attachment and entry remains elusive. Here, by combining the structural analysis of a conspicuous number of crystallized CD81LEL molecules with molecular dynamics simulations, we show that the conformational plasticity of the hCD81LEL head subdomain is a molecular property of the receptor. The observed closed, intermediate, and open conformations of the head subdomain provide distinct binding platforms. Simulations at pH 7.4 and 4.0 indicate that this dynamism is pH modulated. The crystallized double conformation of the disulfide bridge C157-C175 at the base of the head subdomain identifies this bond as the molecular zipper of the plasticity of hCD81LEL. We propose that this conformational dependence of hCD81LEL, which is finely tuned by pH and redox conditions, enables the virus-receptor interactions to diversely re-engage at endosomal conditions. Mechanism of Structural Tuning of the Hepatitis C Virus Human Cellular Receptor CD81 Large Extracellular Loop.,Cunha ES, Sfriso P, Rojas AL, Hospital A, Orozco M, Abrescia NG Structure. 2016 Nov 21. pii: S0969-2126(16)30343-4. doi:, 10.1016/j.str.2016.11.003. PMID:27916518[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||